CHEST 2024
Summaries from CHEST 2024 Annual Meeting, held from October 6 – 9, 2024.
Women with pulmonary arterial hypertension report a high humanistic and clinical burden of disease
Presenter: Vallerie V. McLaughlin, MD, Director, Pulmonary Hypertension Program, University of Michigan Medical School, Ann Arbor, MI.
In an interim analysis of an ongoing observational study, women with pulmonary arterial hypertension (PAH) reported substantial clinical, emotional, psychological, and social impacts, as well as a high economic burden related to the disease.
Identifying “super-responders” could significantly enhance outcomes in patients with systemic sclerosis-associated pulmonary arterial hypertension, researchers say
Presenter: Sumbal Wajid, MBBS, Albany Medical Center, Albany, NY
Tailoring therapies based on individual responses and genetic profiles could promote sustained treatment benefits, improved symptoms, and longer survival in patients with systemic sclerosis-associated pulmonary arterial hypertension, according to authors of a recent literature review on the topic.
Online medical educational activities may improve clinician competence and confidence in managing pulmonary arterial hypertension
Presenter: Margaret Harris, PhD, Director, Clinical Strategy, Medscape, Atlanta, GA
Cardiologists and pulmonologists who participated in an online continuing medical education activity demonstrated significant improvements related to optimal treatment of pulmonary arterial hypertension; however, further education is needed on therapeutic decision-making and interprofessional collaboration.
Many patients with pulmonary arterial hypertension are not receiving guideline-recommended combination therapy, survey suggests
Presenter: Lana Melendres-Groves, MD, Medical Director, Pulmonary Hypertension Program, University of New Mexico, Albuquerque, NM
Despite updated guidelines recommending combination therapy regardless of risk status, a recent survey of pulmonologists and cardiologists revealed that 46% of patients with pulmonary arterial hypertension (PAH) were being treated with monotherapy approaches.
Specialty pharmacy data reveal trends in oral treprostinil initiations and persistence with therapy
Presenter: Daniel J. Lachant, DO, Assistant Professor of Medicine, University of Rochester Medical Center, Rochester, NY
Insights from a specialty pharmacy data set show that transitioning from parenteral treprostinil may be an effective strategy to facilitate tolerability of oral treprostinil—and may in turn lead to higher persistence with therapy.
GLP-1 agonists linked to real-world cardiovascular benefits in patients with co-existing diabetes and COPD
Presenter: Xin Ya See, MD, Department of Medicine, Unity Hospital/Rochester Regional Health, Rochester, N.Y.
GLP-1 agonists reduced cardiovascular risk and mortality in patients with type 2 diabetes mellitus and COPD in a retrospective study, suggesting use of these drugs could be a “game-changer” in this high-risk patient population.